Gabriel Emmanuel M, Sukniam Kulkaew, Popp Kyle, Bagaria Sanjay P
Department of General Surgery, Division of Surgical Oncology, Mayo Clinic, Jacksonville, FL, United States.
Department of General Surgery, Philadelphia College of Osteopathic Medicine, Suwanee, GA, United States.
Front Oncol. 2023 Apr 12;13:1151255. doi: 10.3389/fonc.2023.1151255. eCollection 2023.
Sarcomas comprise a vast and heterogenous group of rare tumors. Because of their diversity, it is challenging to study sarcomas as a whole with regard to their biological and molecular characteristics. This diverse set of tumors may also possess differences related to their tumor-associated vasculature, which in turn may impact the ability to deliver systemic therapies (e.g., chemotherapy, targeted therapies, and immunotherapy). Consequently, response to systemic treatment may also be variable as these depend on the ability of the therapy to reach the tumor target the tumor-associated vasculature. There is a paucity of data regarding sarcoma-related tumor vessels, likely in part to the rarity and heterogeneity of this cancer as well as the previously limited ability to image tumor-associated vessels in real time. Our group has previously utilized confocal fluorescent imaging technology to observe and characterize tumor-associated vessels in real time during surgical resection of tumors, including cutaneous melanoma and carcinomatosis implants derived from gastrointestinal, gynecological, or primary peritoneal (e.g., mesothelioma) tumors. Our prior studies have demonstrated the feasibility of real-time, human intravital microscopy in the study of these tumor types, leading to early but important new data regarding tumor vessel characteristics and their potential implications on drug delivery and efficacy. In this brief report, we present our latest descriptive findings in a cohort of patients with sarcoma who underwent surgical resection and real-time, intravital microscopy of their tumors. Overall, intravital imaging was feasible during the surgical resection of large sarcomas.
ClinicalTrials.gov, identifier NCT03517852; ClinicalTrials.gov, identifier NCT03823144.
肉瘤是一大类罕见且异质性的肿瘤。由于其多样性,从生物学和分子特征方面对肉瘤进行整体研究具有挑战性。这组多样的肿瘤在其肿瘤相关脉管系统方面也可能存在差异,而这反过来可能会影响全身治疗(如化疗、靶向治疗和免疫治疗)的给药能力。因此,对全身治疗的反应也可能各不相同,因为这些反应取决于治疗药物到达肿瘤靶点(肿瘤相关脉管系统)的能力。关于肉瘤相关肿瘤血管的数据匮乏,这可能部分归因于这种癌症的罕见性和异质性,以及此前实时成像肿瘤相关血管的能力有限。我们团队此前利用共聚焦荧光成像技术在肿瘤手术切除过程中实时观察和表征肿瘤相关血管,这些肿瘤包括皮肤黑色素瘤以及源自胃肠道、妇科或原发性腹膜(如间皮瘤)肿瘤的癌性植入物。我们之前的研究已证明在这些肿瘤类型的研究中进行实时人体活体显微镜检查是可行的,从而得出了关于肿瘤血管特征及其对药物递送和疗效潜在影响的早期但重要的新数据。在本简要报告中,我们展示了一组接受肿瘤手术切除及实时活体显微镜检查的肉瘤患者的最新描述性研究结果。总体而言,在大型肉瘤手术切除过程中进行活体成像可行。
ClinicalTrials.gov,标识符NCT03517852;ClinicalTrials.gov,标识符NCT03823144。